González Nieves, Mantey Samuel A, Pradhan Tapas K, Sancho Veronica, Moody Terry W, Coy David H, Jensen Robert T
Digestive Diseases Branch, NIDDK, and Department of Health and Human Services, National Institutes of Health, Bethesda, MD 20892-1804, United States.
Peptides. 2009 Aug;30(8):1473-86. doi: 10.1016/j.peptides.2009.05.007. Epub 2009 May 20.
The mammalian bombesin (Bn) peptides neuromedin B (NMB) and gastrin-releasing peptide (GRP) actions are mediated by two receptors (NMB-receptor, GRP-receptor) which are widely distributed in the GI tract and CNS. From primarily animal studies NMB/GRP-receptor activation has physiological/pathophysiological effects in the CNS and GI tract including stimulating of growth of cancers and normal tissues. Whereas these Bn-receptors' effects have been extensively studied in nonhuman cells and animals, little is known of the physiological/pathological role(s) in humans, largely due to lack of potent antagonists. To address this issue we compared NMB/GRP-receptor affinity/potency of 10 chemical classes of putative antagonists (35 compounds) for human Bn-receptors by performing binding studies or assessing abilities to activate hGRP/hNMB-receptor [assessing phospholipase C activation] in four different cells containing native Bn-receptors or transfected receptors. From binding studies 23 were GRP-receptor-preferring, 4 were NMB-receptor, and 8 nonselective. For the hGRP-receptor-preferring analogues none showed hGRP-receptor agonist activity, but 13 were full or partial hNMB-receptor agonists at hNMB-receptors. For hNMB-receptor-preferring analogues none were agonists. Analogue #24 ([(3-Ph-Pr(6)), His(7), d-Ala(11), d-Pro(13), Psi(13-14), Phe(14)]Bn(6-14)NH2) and analogue #7 [d-Phe(6), Leu(13), Psi(CH(2)NH), Cpa(14)]Bn(6-14) were the most potent (0.2-1.4nM) and selective (>10,000-fold) for the hGRP-receptor with analogue #7.5 [d-Tpi(6), Leu(13), Psi(CH2NH), Leu(14)]Bn(6-14)[RC-3095] (0.2-1.4nM) slightly less selective. Analogue #34 (PD168368) had the highest affinity for hNMB-receptor (1.32-1.58nM) and the greatest selectivity (2298-6952-fold) for the hNMB-receptor. These results demonstrate numerous putative hGRP/hNMB-receptor antagonists identified in nonhuman cells and/or animals have agonist activity at the hNMB-receptor, limiting their potential usefulness. However, a number were identified which were potent/selective for human Bn-receptors and should be useful for investigating their roles in human physiological/pathophysiological conditions.
哺乳动物的铃蟾肽(Bn)类肽神经介素B(NMB)和胃泌素释放肽(GRP)的作用是由两种受体(NMB受体、GRP受体)介导的,这两种受体广泛分布于胃肠道和中枢神经系统。主要基于动物研究,NMB/GRP受体激活在中枢神经系统和胃肠道具有生理/病理生理作用,包括刺激癌症和正常组织的生长。尽管这些Bn受体的作用已在非人类细胞和动物中得到广泛研究,但对其在人类生理/病理作用却知之甚少,这主要是由于缺乏有效的拮抗剂。为了解决这个问题,我们通过进行结合研究或评估在四种含有天然Bn受体或转染受体的不同细胞中激活hGRP/hNMB受体的能力(评估磷脂酶C激活),比较了10类化学结构的假定拮抗剂(35种化合物)对人Bn受体的NMB/GRP受体亲和力/效价。结合研究表明,23种对GRP受体具有偏好性,4种对NMB受体具有偏好性,8种无选择性。对于偏好hGRP受体的类似物,没有一种表现出hGRP受体激动剂活性,但有13种在hNMB受体上是完全或部分hNMB受体激动剂。对于偏好hNMB受体的类似物,没有一种是激动剂。类似物#24([(3-Ph-Pr(6)), His(7), d-Ala(11), d-Pro(13), Psi(13-14), Phe(14)]Bn(6-14)NH2)和类似物#7 [d-Phe(6), Leu(13), Psi(CH(2)NH), Cpa(14)]Bn(6-14)对hGRP受体的效力最强(0.2 - 1.4 nM)且选择性最高(>10,000倍),类似物#7.5 [d-Tpi(6), Leu(13), Psi(CH2NH), Leu(14)]Bn(6-14)[RC-3095](0.2 - 1.4 nM)的选择性稍低。类似物#34(PD168368)对hNMB受体具有最高亲和力(1.32 - 1.58 nM),对hNMB受体的选择性最大(2298 - 6952倍)。这些结果表明,在非人类细胞和/或动物中鉴定出的众多假定的hGRP/hNMB受体拮抗剂在hNMB受体上具有激动剂活性,限制了它们的潜在用途。然而,已鉴定出一些对人Bn受体具有强效/选择性的拮抗剂,它们应有助于研究其在人类生理/病理生理状况中的作用。